Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
Pharmaceutical Engineering: At the Frontier of Drug Substance and Drug Product

Pharmaceutical Engineering: At the Frontier of Drug Substance and Drug Product

PE XVII

Date of beginning

Sunday, 03 May 2020

Duration

5 days

Deadline for abstracts

Tuesday, 31 March 2020

City

Irsee

Country

Germany

Contact

Noel Parsons Jr

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Expected participants

300

Memo

It is well known that the physical and chemical properties of the DS (API) have major impacts on the formulation and the Drug Product (DP) process. In any dosage form including solid, liquid and semi-solid, the Drug Substance (DS) or Active Pharmaceutical Ingredient (API) goes through a formulation process. This process to make the final drug product serves many purposes, but all with the goal of eventually delivering the active ingredient to the desired sites in the patients’ body in the most convenient way and to achieve optimal therapeutic effect. For most small molecule drugs, the final step in an arduous synthetic sequence is usually the crystallization or precipitation of the DS. This serves as both an isolation as well as purification step. In addition, many particle engineering techniques have been advanced that can tailor the physical and chemical properties of the drug substance during the final step in order to facilitate the design and scaleup of a rugged and reproducible DP processes. From historical and regulatory viewpoints, the blurring of the DS/DP interface while having the potential to offer competitive advantages, there will be regulatory and cultural hurdles that need to be ameliorated. The impact of DS properties on DP performance and the DP processes have attracted wide interest in the industry. However, many engineering issues and mechanistic understanding concerning the DS, the formulation, and their interface still need to be developed and explored. This conference seeks to bring scientists, engineers and regulators working at this critical interface for mutual discussion of current results, future improvement and to identify any technical and regulatory needs that still exist. Participants attending this conference will significantly benefit from learning the innovations from the integration of DS (API) and the formulation of the drug product.